Rapid technological advances are expanding the methodological and translational potential of cancer research and medicine. The application of engineering principles to biological problems is recognized as a key driver for transforming basic discoveries in life sciences into real-world solutions that can provide significant strides in addressing disease prevention, early detection, diagnosis, drug discovery and personalized therapies.
The Cross-Topic Biomedical Engineering and Technology Development at DKFZ builds on strengths in spatial and single-cell multi-omics, organoid and organ-on-chip platforms, cell engineering, synthetic immunology, robotics, optical and sensor technologies, and radiological sciences (DKFZ Research Topics). A central ambition is to move beyond static diagnostic and therapeutic paradigms toward technologies that continuously sense, interpret, and respond to dynamic biological signals throughout the patient journey. This includes fundamental breakthroughs in AI-enabled analytics and clinical decision support, digital biomarkers, innovative medical devices for early detection and personalized intervention, and wearable models and organoid systems that will further accelerate functional testing and translational research.
A key structural element is the new DKFZ site in Dresden with a focus on oncoengineering. In partnership with the Dresden University of Technology and Helmholtz Zentrum Dresden Rossendorf (HZDR), it will advance biomedical sensing and robotics technologies from nano- and microscale systems for therapeutic monitoring and targeted drug delivery to AI-powered next-generation surgical robots and intraoperative imaging methods, towards the perspective of an agentic operating room in future.
Along the translational value chain, the Cross-Topic is embedded within the national translational platforms DKTK and NCT, and will be closely linked to innovation structures such as the planned IT³E.factory, an integrated biotechnology incubator and accelerator for enabling scalable translation to strengthen industrial and clinical implementation.
The Cross-Topic is integrated into national and international initiatives, for instance the Excellence clusters with university partners (SynthImmune, CeTi) and the Helmholtz Biomedical Engineering Initiative. Integration into regional degree and training programs in Dresden and Heidelberg foster a strong ecosystem for biomedical scientists, engineers and clinical scientists.
